Single dose study of SHR-1894 in healthy volunteers
Part of Skin clinical trials.
This trial tests a single injection of a new medicine called SHR-1894 in healthy people to see how safe it is and how the body processes it. It helps find the right dose for future studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old.
- You are generally healthy, with no major medical conditions.
- Your weight is above 50 kg (110 lbs) for men or 45 kg (99 lbs) for women, with a BMI between 19 and 26.
- You have not taken any medications (including over-the-counter, herbs, or supplements) in the last 2 weeks.
- You agree to use effective birth control or abstain from sex during the study and for a period after.
- You have not donated blood (over 400 mL) in the last 8 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a single dose of a new drug called SHR-7012 in healthy volunteers to check if it is safe and how the body handles it. It is a first-in-human trial, so participants will be closely monitored.
This trial tests how a new medicine (SHR-3167) is absorbed by the body and checks for side effects. Healthy volunteers ages 18-55 can join to help researchers understand how this drug works.
This trial tests a new drug called SHR-1905 for people with moderate-to-severe atopic dermatitis (a type of eczema). It aims to see if the drug is safe and helps improve symptoms.
This study tests a new investigational drug, called HRS-8797, in healthy people to see how safe it is and how the body processes it. It's an early-phase trial, so you may not directly benefit, but your participation can help find new treatments for future patients.
This trial tests an injectable medicine called SHR-1819 for teenagers aged 12 to 17 with severe atopic dermatitis (eczema) that has not responded well to creams or other treatments. The goal is to see if it can improve skin symptoms and reduce itching.
This study tests a new investigational drug called ISH0613 in healthy volunteers to see if it is safe and how the body processes it. It is the first time this drug is given to humans.
Hear when a new Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.